Tiffany Sia, MD, on Procedural Interventions for Gynecologic Malignancies With Oligoprogressive Disease During ICI


Tiffany Sia, MD, spoke about major takeaways from her study and how to implement procedural interventions for patients with gynecologic malignancies who have oligoprogression.

CancerNetwork® spoke with Tiffany Sia, MD, a gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center in New York, during the 2022 Annual Global Meeting of the International Gynecologic Cancer Society about different procedural interventions used across 887 patients with gynecologic malignancies who experienced oligoprogression during treatment with immune checkpoint inhibitors (ICI) at her institution. In a chart review, interventions included either surgical resection (n = 10), interval radiation (IR) ablation (n = 3), or radiation therapy (n = 28) in 41 total patients who received ICI and had oligoprogressive disease. These types of interventions appeared to benefit this patient subset and offers evidence for working them into treatment for better survival outcomes.


What we found is that the patients who were treated with either surgical procedures, radiation therapies, or IR-guided ablations had very favorable outcomes overall. We would recommend that we can continue to treat these patients with oligoprogression with combined modalities of immune checkpoint blockade and consider these procedural interventions for localized oligoprogression.

The take-home point is that this is feasible and the patients overall have good outcomes. We should not rule out the possibility of an interventional procedure just because a patient is on immune checkpoint blockade; it is doable. This is an ongoing field of study. The number of patients in our cohort is relatively small, but as more and more patients being treated with these types of drugs and seeing responses, we might have more patients with oligoprogression. This is going to be an interesting question moving forward.


Sia T, Wan V, Zivanovec O, et al. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies. Presented at the Annual Global Meeting of the International Gynecologic Cancer Society; New York, NY; September 29-October 1, 2022. Poster FP014.

Related Videos
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Related Content